EX-99.1
2
exhibit_99.htm
PRESS RELEASE ISSUED ON APRIL 1, 2008
News Release
April 1, 2008
Alpharma Completes Sale of Active Pharmaceutical Ingredients Business
Bridgewater, NJ April 1, 2008
Alpharma Inc. (NYSE:ALO), a leading global specialty pharmaceutical company, announced today that the divestiture of its Active Pharmaceutical Ingredients ("API") business to 3i (III:LSE) has been completed for a purchase price of $395 million and net after-tax proceeds of approximately $365 million.
The Company's API business develops, manufactures and markets a line of fermentation-based active pharmaceutical ingredients and one chemically-synthesized active pharmaceutical ingredient that are used, primarily by third parties, in the manufacture of finished dose pharmaceutical products. The business reported full year 2007 revenues of $187.6 million and operating income of $34.0 million. The sale includes manufacturing facilities in Copenhagen, Denmark; Oslo, Norway; Budapest, Hungary; and Taizhou, China; and the business employs approximately 700 people.
Contact
:
Jack Howarth
Vice President, Investor Relations
908-566-4153
Jack.howarth@alpharma.com
Alpharma press releases are available at our website
www.alpharma.com
About Alpharma
Alpharma Inc. (NYSE: ALO) is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 80 countries. Alpharma has a growing branded pharmaceutical franchise in the U.S. pain market with its KADIAN
®
(morphine sulfate extended-release) Capsules, and the FLECTOR
®
Patch (diclofenac epolamine topical patch). Alpharma is also internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.

EX - 99 . 1 2 exhibit _ 99 . htm PRESS RELEASE ISSUED ON APRIL 1 , 2008 News Release April 1 , 2008 Alpharma Completes Sale of Active Pharmaceutical Ingredients Business Bridgewater , NJ April 1 , 2008 Alpharma Inc . ( NYSE : ALO ) , a leading global specialty pharmaceutical company , announced today that the divestiture of its Active Pharmaceutical Ingredients ( " API " ) business to 3i ( III : LSE ) has been completed for a purchase price of $ 395 million and net after - tax proceeds of approximately $ 365 million . The Company 's API business develops , manufactures and markets a line of fermentation - based active pharmaceutical ingredients and one chemically - synthesized active pharmaceutical ingredient that are used , primarily by third parties , in the manufacture of finished dose pharmaceutical products . The business reported full year 2007 revenues of $ 187.6 million and operating income of $ 34.0 million . The sale includes manufacturing facilities in Copenhagen , Denmark ; Oslo , Norway ; Budapest , Hungary ; and Taizhou , China ; and the business employs approximately 700 people . Contact : Jack Howarth Vice President , Investor Relations 908 - 566 - 4153 Jack.howarth@alpharma.com Alpharma press releases are available at our website www.alpharma.com About Alpharma Alpharma Inc . ( NYSE : ALO ) is a global specialty pharmaceutical company with leadership positions in products for humans and animals . Alpharma is presently active in more than 80 countries . Alpharma has a growing branded pharmaceutical franchise in the U . S . pain market with its KADIAN ® ( morphine sulfate extended - release ) Capsules , and the FLECTOR ® Patch ( diclofenac epolamine topical patch ) . Alpharma is also internationally recognized as a leading provider of pharmaceutical products for poultry and livestock .